CURRENTLY ENROLLING CLINICAL TRIALS

Clinical Research

Please contact your provider to learn if you are eligible for any of our enrolling clinical trials.  

Benefits to participants

  • Learn more about your condition
  • Get free study-related eye examinations, when appropriate
  • Help others by assisting researchers to find better and more effective treatments
  • Receive possible financial compensation for your time

 

Diabetic Macular Edema in Underrepresented Populations

Elevatum-ML43435 (Sponsor: Genetech)
2022-Present
Office: Teaneck

NCT Number: NCT05224102
This Phase 4 study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treated with faricimab. The study population will consist of participants ≥18 years of age who self-identify as Black/African American, Hispanic/Latino American, or Native American/Alaska Native/Native Hawaiian or other Pacific Islander. 


For more information, click here.

Retinal Vein Occlusion

Quasar – 22153
2023-Present
Office: Teaneck and Edison

NCT Number: NCT05850520
This Phase 3 study is designed to investigate treatment response to high-dose aflibercept (8 mg) vs standard of care (2 mg) in patients with macular edema secondary to retinal vein occlusion via intravitreal (IVT) injections. If the patients’ sight improves, marked by Best Corrected Visual Acuity (BCVA), the intervals of IVT injections will increase as well.

For more information, click here.

Wet AMD

Opthea Shore
2021-Present
Office: Toms River

A Phase 3, Multicenter, Double-Masked, Randomized Study to evaluate the safety and efficacy of IVT OPT-302 in Combination with Ranizumab, Compared to Ranizumab Alone, in participants with neovascular age-related macular degeneration, and is sponsored by Opthea Pharmaceuticals.

Opthea Coast
2021-Present
Office: Edison

A Phase 3, Multicenter, Double-Masked, Randomized Study to evaluate the safety and efficacy of IVT OPT-302 in Combination with Aflibercept, Compared to Aflibercept Alone, in participants with neovascular age-related macular degeneration, and is sponsored by Opthea.

Questions?
Contact us today! We’re here to help!

Loading ...

©All Rights Reserved. NJRetina 2024